Contact
searchSearch
HMP Global
Login
Quiz

Quiz: How Common are Incidental Thyroid Nodules?

03/18/2022

Recent News

FDA Approval
FDA Expands Talazoparib Plus Enzalutamide Indication to HRR-Mutated Metastatic Prostate Cancer
10/26/2026
Emily Estrada
Based on results from the phase 3 TALAPRO-3 trial, the FDA has approved talazoparib plus enzalutamide for patients with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, following a significant...
Based on results from the phase 3 TALAPRO-3 trial, the FDA has approved talazoparib plus enzalutamide for patients with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, following a significant...
Based on results from the phase...
10/26/2026
Oncology
News
Reduced-Frequency Immunotherapy Fails to Demonstrate Noninferiority in Advanced Cancer in Phase 3 MOIO Trial
10/26/2026
Emily Estrada
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO...
10/26/2026
Oncology
News
Risvutatug Rezetecan Reduces Progression Risk by 67% in Previously Treated Relapsed or Refractory Osteosarcoma
10/26/2026
Emily Estrada
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3...
10/26/2026
Oncology
News
Sacituzumab Tirumotecan Outperforms Chemotherapy in Advanced or Recurrent Endometrial Cancer
10/26/2026
Stephanie Holland
Results from the phase 3 TroFuse-005 trial demonstrated significant improvements in survival and response with sacituzumab tirumotecan compared with physician's choice chemotherapy in previously treated advanced or recurrent endometrial...
Results from the phase 3 TroFuse-005 trial demonstrated significant improvements in survival and response with sacituzumab tirumotecan compared with physician's choice chemotherapy in previously treated advanced or recurrent endometrial...
Results from the phase 3...
10/26/2026
Oncology
News
Phase 3 Trial Demonstrates Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Biliary Tract Cancer
10/25/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that ivonescimab plus gemcitabine and cisplatin significantly improved survival and response compared with durvalumab plus chemotherapy in advanced biliary tract cancer, supporting the PD-1/VEGF...
Results from a phase 3 trial demonstrated that ivonescimab plus gemcitabine and cisplatin significantly improved survival and response compared with durvalumab plus chemotherapy in advanced biliary tract cancer, supporting the PD-1/VEGF...
Results from a phase 3 trial...
10/25/2026
Oncology
News
Sonesitatug Vedotin Significantly Improves Overall Survival in CLDN18.2-Positive Advanced Gastroesophageal Cancer
10/25/2026
Stephanie Holland
Results from the phase 3 CLARITY-Gastric 01 trial demonstrated significant overall survival benefits with sonesitatug vedotin in previously treated CLDN18.2-positive advanced gastroesophageal cancer, supporting the antibody-drug conjugate as...
Results from the phase 3 CLARITY-Gastric 01 trial demonstrated significant overall survival benefits with sonesitatug vedotin in previously treated CLDN18.2-positive advanced gastroesophageal cancer, supporting the antibody-drug conjugate as...
Results from the phase 3...
10/25/2026
Oncology
News
Osimertinib Plus Savolitinib Outperforms Chemotherapy in EGFR-Mutated, MET-Altered Advanced NSCLC Following Osimertinib
10/25/2026
Stephanie Holland
Results from the phase 3 SAFFRON trial demonstrated that osimertinib plus savolitinib significantly improved survival compared with platinum-based chemotherapy in patients with EGFR-mutated, MET-altered advanced non-small cell lung cancer...
Results from the phase 3 SAFFRON trial demonstrated that osimertinib plus savolitinib significantly improved survival compared with platinum-based chemotherapy in patients with EGFR-mutated, MET-altered advanced non-small cell lung cancer...
Results from the phase 3 SAFFRON...
10/25/2026
Oncology
News
Longer Follow-Up From HERIZON-GEA-01 Reinforces Survival Benefit of Zanidatamab-Based Regimens
10/25/2026
Stephanie Holland
Updated results from the phase 3 HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy significantly improved overall survival compared with trastuzumab plus chemotherapy in previously untreated patients with HER2-positive...
Updated results from the phase 3 HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy significantly improved overall survival compared with trastuzumab plus chemotherapy in previously untreated patients with HER2-positive...
Updated results from the phase 3...
10/25/2026
Oncology
News
Darolutamide Plus ADT and Radiotherapy Significantly Improves Metastasis-Free Survival in High-Risk Prostate Cancer
10/24/2026
Stephanie Holland
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP...
10/24/2026
Oncology
News
Tarlatamab Plus Durvalumab Significantly Improves Overall Survival in Patients With Extensive-Stage Small Cell Lung Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3...
10/24/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use